Core Viewpoint - Corning Hospital (02120.HK) announced a share buyback on December 15, spending HKD 279,000 to repurchase 25,000 shares at a price of HKD 11.2 per share [1] Summary by Category - **Company Actions** - The company executed a buyback of 25,000 shares at a total cost of HKD 279,000 [1] - The repurchase price per share was set at HKD 11.2 [1]

证券日报网讯 12月15日晚间，迪安诊断发布公告称，公司第五届董事会第十七次会议审议通过《关于 取消监事会、修订及废止部分公司治理制度的议案》《关于修订、新增部分公司治理制度的议案》《关 于召开2025年第一次临时股东大会的议案》等多项议案。 （文章来源：证券日报） ...

Core Viewpoint - The Beijing Municipal Health Commission issued a response to complaints regarding cancer detection failures during health check-ups, concluding that there were no instances of misdiagnosis or data falsification by the involved medical institutions [2][3]. Group 1: Investigation Findings - The investigation found that the tumor marker (Carcinoembryonic Antigen, CEA) test results from Beijing Aikang Guobin were consistent with original measurements and traceable [3]. - CEA is a non-organ-specific tumor marker, and elevated levels can indicate various cancers, but normal levels do not rule out malignancies [4]. - The investigation revealed that Dr. Yang Yongkun from Peking Jishuitan Hospital violated regulations by improperly referring patients, leading to disciplinary actions against him [4]. Group 2: Institutional Issues - Beijing Aikang Guobin's Xisanqi clinic was found to have issues such as improper registration of multi-practice physicians and incomplete health check reports, prompting a supervisory notice [5]. - The Xinne clinic of Beijing Aikang Guobin faced a warning and a fine of 2,000 RMB for non-compliance with health standards regarding medical waste storage [5]. - Due to objections raised by the complainant, the Beijing Municipal Health Commission plans to conduct further medical accident technical assessments involving multiple medical institutions [6].

Group 1 - The core viewpoint of the news is that Langma Information (300288) has experienced a significant decline in both revenue and net profit for the first three quarters of 2025, indicating potential challenges in its business operations [2]. - As of December 15, 2025, Langma Information's stock closed at 13.2 yuan, down 2.08%, with a turnover rate of 1.63% and a trading volume of 41,700 hands, amounting to a transaction value of 55.52 million yuan [1]. - The company's main business includes medical services and internet medical services, which encompass physical medical institutions, medical information services, internet hospital services, IPTV smart medical family health service platforms, smart wearable devices, and pharmaceutical circulation [2]. Group 2 - For the first three quarters of 2025, Langma Information reported a main operating income of 224 million yuan, a year-on-year decrease of 24.75%, and a net profit attributable to shareholders of 13.51 million yuan, down 67.04% year-on-year [2]. - In the third quarter of 2025, the company recorded a single-quarter main operating income of 72.53 million yuan, a year-on-year decline of 36.46%, and a net profit attributable to shareholders of -0.93 million yuan, reflecting a year-on-year decrease of 105.48% [2]. - The company's debt ratio stands at 17.27%, with investment income of 16.99 million yuan and financial expenses of -2.53 million yuan, while the gross profit margin is reported at 29.25% [2].

海吉亚医疗公告将动用回购授权，以不时在公开市场上以不少于人民币3亿元的总价格回购本公司股 份，以实际行动传递对公司内在价值的认可和长远发展的坚定信心。未来，公司还将视市场情况，持续 优化股东回报，在回购、分红及并购扩张中做出更高效的、更有利于股东价值的资本配置安排。 ...

Company News - China Shenhua (01088.HK) reported coal sales of 389.5 million tons for the first 11 months, a decrease of 7.7% year-on-year. November sales were 37 million tons, down 3.6% year-on-year [1] - China Metallurgical Group (01618.HK) signed new contracts worth RMB 958.13 billion in the first 11 months, an 8.6% decrease year-on-year, with overseas contracts amounting to RMB 75 billion, a 0.4% increase year-on-year [1] - China Eastern Airlines (00670.HK) saw a 6.51% year-on-year increase in passenger capacity in November, with passenger turnover up 10.35% year-on-year and a seat load factor of 87.37%, up 3.04 percentage points year-on-year [1] - China Southern Airlines (01055.HK) reported an 8.68% year-on-year increase in passenger capacity in November, with passenger turnover up 10.42% year-on-year and a seat load factor of 86.29%, up 1.36 percentage points year-on-year [1] - New China Life Insurance (01336.HK) recorded cumulative original insurance premium income of RMB 188.85 billion for the first 11 months, a 16% year-on-year increase [1] - AOS Group (01161.HK) announced annual results for the year ending September 30, 2025, with revenue of approximately HKD 981 million, a decrease of 0.19% year-on-year, and a net profit of HKD 80.887 million, a 19% year-on-year increase [1] - Hopson Development Holdings (00754.HK) reported total contract sales of approximately RMB 14.27 billion for the first 11 months, an 8.91% decrease year-on-year [1] - Agile Group (01813.HK) had a pre-sale amount of RMB 511 million in November, a decrease of 21.4% year-on-year [1] - Galen Pharmaceuticals (01672.HK) is expected to become a best-in-class oral small molecule IL-17 inhibitor, with positive topline results from its Phase I study in the U.S. [1] - Bole Technology (02592.HK) submitted a new drug clinical trial application for CBT-199 to the U.S. FDA [1] - China Supply Chain Industry (03708.HK) signed a strategic cooperation framework agreement with Golden Energy regarding digital assets [1] - Times China Holdings (01233.HK) had its liquidation petition withdrawn [1] - Botai Car Union (02889.HK) received a first project designation notice from a leading domestic new energy vehicle client [1] Buyback Activities - Haijia Medical (06078.HK) plans to repurchase 10% of its issued shares, with a repurchase amount of no less than RMB 300 million [1] - Tencent Holdings (00700.HK) repurchased 1.051 million shares for HKD 636 million, with repurchase prices ranging from HKD 602.5 to HKD 608 [1] - Xiaomi Group (01810.HK) repurchased 7.2 million shares for HKD 302 million, with repurchase prices ranging from HKD 41.78 to HKD 42 [1] Share Cancellation - Pacific Shipping (02343.HK) canceled 23.739 million repurchased shares [2]

Core Viewpoint - Tongce Medical (600763) reported a slight decline in stock price, with a closing price of 40.25 yuan on December 15, 2025, down 0.57% [1] Financial Performance - For the first three quarters of 2025, Tongce Medical achieved a main revenue of 2.29 billion yuan, an increase of 2.56% year-on-year [2] - The net profit attributable to shareholders was 514 million yuan, up 3.16% year-on-year, while the net profit excluding non-recurring items was 509 million yuan, increasing by 3.09% year-on-year [2] - In Q3 2025, the company reported a single-quarter main revenue of 842 million yuan, a year-on-year increase of 2.34% [2] - The single-quarter net profit attributable to shareholders was 192 million yuan, up 2.31% year-on-year, and the net profit excluding non-recurring items was also 192 million yuan, increasing by 1.85% year-on-year [2] - The company's debt ratio stands at 25.1%, with investment income of 41.22 million yuan and financial expenses of 31.93 million yuan [2] - The gross profit margin is reported at 41.69% [2] Market Activity - On December 15, 2025, the net inflow of main funds was 1.6042 million yuan, accounting for 1.15% of the total transaction amount, while retail funds saw a net inflow of 9.405 million yuan, making up 6.74% of the total transaction amount [1] - Conversely, speculative funds experienced a net outflow of 11.0092 million yuan, representing 7.89% of the total transaction amount [1] Analyst Ratings - In the last 90 days, seven institutions provided ratings for Tongce Medical, with four giving a "buy" rating and three an "increase" rating [2] - The average target price set by institutions over the past 90 days is 5.288 billion yuan [2]

Group 1 - The core viewpoint of the article is that Aoyang Health has completed the divestiture of its chemical fiber business and is now focused on medical services and pharmaceutical logistics [1] Group 2 - Aoyang Health's current main business operations are in the fields of medical services and pharmaceutical logistics following the divestiture [1]

本公司认为，股份目前的交易价格并未反映其内在价值或本公司的实际业务前景。因此，本公司董事会 已议决利用购回授权，以不时在公开市场上按不少于人民币3亿元的总价格购回股份。本公司认为，建 议股份购回将展现本公司对其自身业务发展前景充满信心，而本公司现有财务资源将足以支持实施建议 股份购回，同时维持稳健的财务状况。本公司将视市场情况，持续优化股东回报，在回购、分红及併购 扩张中做出更高效的、更有利于股东价值的资本配置安排。 海吉亚医疗(06078)发布公告，就有关本公司股东于本公司于2025年6月27日举行的股东周年大会授出的 购回本公司股份的一般授权的相关事宜。根据购回授权，本公司获准于香港联合交易所有限公司购回最 多6184.99万股股份，占于股东周年大会日期已发行股份(不包括库存股份)总数的10%。 ...

格隆汇12月15日丨海吉亚医疗(06078.HK)公告，公司认为股份目前的交易价格并未反映其内在价值或公 司的实际业务前景。因此，公司董事会已议决利用购回授权，以不时在公开市场上按不少于人民币300 百万元的总价格购回股份。 ...